Voxcan is a preclinical CRO with 14 years of experience in performing efficacy and biodistribution studies in three areas: Oncology, Infectious diseases and Medical Devices. With 400m² of BSL-2 and BSL-3 facilities, we provide a large variety of characterized tumor, bacterial and viral models (including SARS-CoV-2) to test new compounds and cell therapies, in addition of testing medical devices performance and degradation (dermal fillers, osteoarticular implants). Our core expertise in high-resolution imaging (bioluminescence, fluorescence, CT, micro-CT) enables to follow compound efficacy and biodistribution in a longitudinal manner, thereby increasing measurement accuracy, saving time and costs. By providing high-technology readouts, our ultimate goal is to help Pharma, Biotech and Medical Device companies accelerate the time-to-market of their candidate therapies.